Subros Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 12, 2025, 11:32 am

Competitors of Subros Ltd

All Competitor Stocks of Subros Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:40 am

Below is a detailed analysis of the quarterly data for Subros Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 908.00 Cr.. The value appears strong and on an upward trend. It has increased from 821.00 Cr. (Dec 2024) to 908.00 Cr., marking an increase of 87.00 Cr..
• For Expenses, as of Mar 2025, the value is 816.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 745.00 Cr. (Dec 2024) to 816.00 Cr., marking an increase of 71.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 93.00 Cr.. The value appears strong and on an upward trend. It has increased from 76.00 Cr. (Dec 2024) to 93.00 Cr., marking an increase of 17.00 Cr..
• For OPM %, as of Mar 2025, the value is 10.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Dec 2024) to 10.00%, marking an increase of 1.00%.
• For Other Income, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Dec 2024) to 6.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 3.00 Cr..
• For Depreciation, as of Mar 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.00 Cr. (Dec 2024) to 34.00 Cr., marking an increase of 2.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 62.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Dec 2024) to 62.00 Cr., marking an increase of 16.00 Cr..
• For Tax %, as of Mar 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Dec 2024) to 25.00%, marking a decrease of 3.00%.
• For Net Profit, as of Mar 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Dec 2024) to 46.00 Cr., marking an increase of 13.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 7.08. The value appears strong and on an upward trend. It has increased from 5.05 (Dec 2024) to 7.08, marking an increase of 2.03.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:56 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:17 am

Below is a detailed analysis of the balance sheet data for Subros Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,081.00 Cr.. The value appears strong and on an upward trend. It has increased from 943.00 Cr. (Mar 2024) to 1,081.00 Cr., marking an increase of 138.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 4.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 764.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 690.00 Cr. (Mar 2024) to 764.00 Cr., marking an increase of 74.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,859.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,651.00 Cr. (Mar 2024) to 1,859.00 Cr., marking an increase of 208.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 748.00 Cr.. The value appears strong and on an upward trend. It has increased from 745.00 Cr. (Mar 2024) to 748.00 Cr., marking an increase of 3.00 Cr..
• For CWIP, as of Mar 2025, the value is 50.00 Cr.. The value appears to be declining and may need further review. It has decreased from 80.00 Cr. (Mar 2024) to 50.00 Cr., marking a decrease of 30.00 Cr..
• For Investments, as of Mar 2025, the value is 116.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2024) to 116.00 Cr., marking an increase of 111.00 Cr..
• For Other Assets, as of Mar 2025, the value is 945.00 Cr.. The value appears strong and on an upward trend. It has increased from 821.00 Cr. (Mar 2024) to 945.00 Cr., marking an increase of 124.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,859.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,651.00 Cr. (Mar 2024) to 1,859.00 Cr., marking an increase of 208.00 Cr..

Notably, the Reserves (1,081.00 Cr.) exceed the Borrowings (1.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Subros Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 23.07. This value is within the healthy range. It has increased from 14.96 (Mar 24) to 23.07, marking an increase of 8.11.
• For Diluted EPS (Rs.), as of Mar 25, the value is 23.07. This value is within the healthy range. It has increased from 14.96 (Mar 24) to 23.07, marking an increase of 8.11.
• For Cash EPS (Rs.), as of Mar 25, the value is 42.68. This value is within the healthy range. It has increased from 32.81 (Mar 24) to 42.68, marking an increase of 9.87.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 167.68. It has increased from 146.54 (Mar 24) to 167.68, marking an increase of 21.14.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 167.68. It has increased from 146.54 (Mar 24) to 167.68, marking an increase of 21.14.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 516.10. It has increased from 470.69 (Mar 24) to 516.10, marking an increase of 45.41.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 52.57. This value is within the healthy range. It has increased from 41.20 (Mar 24) to 52.57, marking an increase of 11.37.
• For PBIT / Share (Rs.), as of Mar 25, the value is 32.93. This value is within the healthy range. It has increased from 23.34 (Mar 24) to 32.93, marking an increase of 9.59.
• For PBT / Share (Rs.), as of Mar 25, the value is 31.17. This value is within the healthy range. It has increased from 21.55 (Mar 24) to 31.17, marking an increase of 9.62.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 23.04. This value is within the healthy range. It has increased from 14.95 (Mar 24) to 23.04, marking an increase of 8.09.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 23.07. This value is within the healthy range. It has increased from 14.96 (Mar 24) to 23.07, marking an increase of 8.11.
• For PBDIT Margin (%), as of Mar 25, the value is 10.18. This value is within the healthy range. It has increased from 8.75 (Mar 24) to 10.18, marking an increase of 1.43.
• For PBIT Margin (%), as of Mar 25, the value is 6.38. This value is below the healthy minimum of 10. It has increased from 4.95 (Mar 24) to 6.38, marking an increase of 1.43.
• For PBT Margin (%), as of Mar 25, the value is 6.03. This value is below the healthy minimum of 10. It has increased from 4.57 (Mar 24) to 6.03, marking an increase of 1.46.
• For Net Profit Margin (%), as of Mar 25, the value is 4.46. This value is below the healthy minimum of 5. It has increased from 3.17 (Mar 24) to 4.46, marking an increase of 1.29.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.46. This value is below the healthy minimum of 8. It has increased from 3.17 (Mar 24) to 4.46, marking an increase of 1.29.
• For Return on Networth / Equity (%), as of Mar 25, the value is 13.75. This value is below the healthy minimum of 15. It has increased from 10.21 (Mar 24) to 13.75, marking an increase of 3.54.
• For Return on Capital Employeed (%), as of Mar 25, the value is 18.50. This value is within the healthy range. It has increased from 14.85 (Mar 24) to 18.50, marking an increase of 3.65.
• For Return On Assets (%), as of Mar 25, the value is 8.09. This value is within the healthy range. It has increased from 5.91 (Mar 24) to 8.09, marking an increase of 2.18.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.92. There is no change compared to the previous period (Mar 24) which recorded 1.92.
• For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.29 (Mar 24) to 1.45, marking an increase of 0.16.
• For Quick Ratio (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has increased from 0.68 (Mar 24) to 0.91, marking an increase of 0.23.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.49. This value is within the healthy range. It has increased from 6.39 (Mar 24) to 6.49, marking an increase of 0.10.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.68 (Mar 24) to 0.00, marking a decrease of 6.68.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 3.04 (Mar 24) to 0.00, marking a decrease of 3.04.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.32 (Mar 24) to 0.00, marking a decrease of 93.32.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 96.96 (Mar 24) to 0.00, marking a decrease of 96.96.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 29.88. This value is within the healthy range. It has increased from 23.03 (Mar 24) to 29.88, marking an increase of 6.85.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 14.09. This value is within the healthy range. It has increased from 9.36 (Mar 24) to 14.09, marking an increase of 4.73.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,578.08. It has increased from 3,237.28 (Mar 24) to 3,578.08, marking an increase of 340.80.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has increased from 1.05 (Mar 24) to 1.06, marking an increase of 0.01.
• For EV / EBITDA (X), as of Mar 25, the value is 10.43. This value is within the healthy range. It has decreased from 12.05 (Mar 24) to 10.43, marking a decrease of 1.62.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.09. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.09.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 93.31 (Mar 24) to 0.00, marking a decrease of 93.31.
• For Price / BV (X), as of Mar 25, the value is 3.34. This value exceeds the healthy maximum of 3. It has decreased from 3.51 (Mar 24) to 3.34, marking a decrease of 0.17.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.09. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.09.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness